levetiracetam + placebo

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Tardive Dyskinesia

Conditions

Tardive Dyskinesia

Trial Timeline

— → —

NCT ID

NCT00291213

About levetiracetam + placebo

levetiracetam + placebo is a phase 3 stage product being developed by UCB for Tardive Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT00291213. Target conditions include Tardive Dyskinesia.

What happened to similar drugs?

3 of 6 similar drugs in Tardive Dyskinesia were approved

Approved (3) Terminated (1) Active (3)

✅Valbenazine Oral CapsuleNeurocrine BiosciencesApproved

🔄NBI-98854Neurocrine BiosciencesPhase 3

✅Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved

🔄NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3

🔄ValbenazineNeurocrine BiosciencesPhase 3

✅Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00291213	Phase 3	Completed	—	—	Tardive Dyskinesia
NCT01228747	Phase 3	Completed	Oct 1, 2010	May 1, 2014	Epilepsy
NCT00566046	Phase 3	Terminated	Nov 1, 2007	May 1, 2010	Epilepsy, Post-Traumatic
NCT00291733	Phase 2	UNKNOWN	May 1, 2006	Oct 1, 2007	Levodopa Induced Dyskinesia
NCT00254657	Pre-clinical	Completed	Mar 1, 2004	Apr 1, 2005	Fibromyalgia
NCT00615615	Phase 3	Completed	Sep 1, 1999	Mar 1, 2003	Epilepsy

Competing Products

13 competing products in Tardive Dyskinesia

See all competitors

Product	Company	Stage	Hype Score
Sarizotan	Merck	Pre-clinical	18
Valbenazine	Neurocrine Biosciences	Phase 1	18
Valbenazine Oral Capsule	Neurocrine Biosciences	Approved	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854	Neurocrine Biosciences	Phase 3	37
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Approved	40
NBI-98854	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 3	37
Valbenazine	Neurocrine Biosciences	Phase 3	37
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Approved	40
NBI-1065890 + Placebo	Neurocrine Biosciences	Phase 2	39